Evidence map›Paper›PMID 38828078›Full record

ArticleAcute medicine & surgery

Safety of cannabidiol products as a social issue: A case series.

Yukari Maki, Asuka Tsuchiya, Rie Yamamoto, Takeshi Saito, Seiji Morita, Yoshihide Nakagawa

Abstract readCase Reports
In one paragraph

Article in Acute medicine & surgery. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yukari MakiDepartment of Emergency and Critical Care Medicine Tokai University School of Medicine Isehara Kanagawa Japan.ORCID https://orcid.org/0000-0002-6739-592X
Asuka TsuchiyaDepartment of Emergency and Critical Care Medicine Tokai University School of Medicine Isehara Kanagawa Japan.
Rie YamamotoDepartment of Emergency and Critical Care Medicine Tokai University School of Medicine Isehara Kanagawa Japan.
Takeshi SaitoDepartment of Emergency and Critical Care Medicine Tokai University School of Medicine Isehara Kanagawa Japan.
Seiji MoritaDepartment of Emergency and Critical Care Medicine Tokai University School of Medicine Isehara Kanagawa Japan.
Yoshihide NakagawaDepartment of Emergency and Critical Care Medicine Tokai University School of Medicine Isehara Kanagawa Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Cannabidiol (CBD) products have increased in popularity in Japan in recent years, particularly among young people. Some CBD products contain tetrahydrocannabinol (THC), the main ingredient of cannabis, and its analogs, which are illegal in Japan and have become a social issue. This report discusses the safety of CBD products. Case Presentation: Five patients with symptoms of CBD ingestion, including nausea, presented to our hospital. Three of the products these patients ingested contained THC. Metabolites of THC were detected in the blood and urine of all three patients, although there were some discrepancies in the urine drug screening test (DS10®). These examination results differed even when the same product was consumed. Conclusion: CBD products are unsafe and may unintentionally contain THC. It is also important to understand that CBD can turn into THC, and the effective time needed to conduct urine drug screening.

Indexed as

cannabidiolcannabinoidcannabinoid analogsillegal drugtetrahydrocannabinol

Identifiers

PMID38828078
PMCPMC11142928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.